Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294.SZ)
Shenzhen, CN
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.70% | -7.81% | -35.61% | -31.95% | -45.97% | -32.55% | -26.14% | -6.52% | -4.46% | +30.80% | +364.17% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | -2 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%+7.3% Q1'26: +15.6% (vs Q1'25)
-
EPS growth Medical - Instruments & Supplies: +16.3%+7.4% Q1'26: +11.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+13.0% Q1'26: +3.0% (vs Q1'25)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+14.6% ★ Q1'26: +19.4% (vs Q1'25)
-
ROIC Medical - Instruments & Supplies: +6.0%+9.2% ★ Q1'26: +10.4% (vs Q1'25)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.1% Q1'26: +0.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×0.67× ★ Q1'26: 0.70× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 2 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.48B
est: 3.58B (-2.8%)
|
3.83B
est: 3.86B (-0.8%)
|
4.15B
est: 4.27B (-2.6%)
|
4.65B
est: 4.75B (-2.1%)
|
4.47B
est: 4.42B (+1.2%)
|
2.74B
est: 3.12B (-12.4%)
|
3.06B
est: 2.88B (+6.4%)
|
3.48B
est: 3.54B (-1.7%)
|
3.37B
est: 3.61B (-6.8%)
|
4.01B
est: 4.02B (-0.3%)
|
4.31B
est: 4.43B (-2.7%)
|
5.28B
5.28B – 5.28B
+19.4% YoY
|
6.47B
6.47B – 6.47B
+22.4% YoY
|
7.75B
7.75B – 7.75B
+19.8% YoY
|
| EBITDA |
1.53B
est: 887.25M (+72.2%)
|
1.71B
est: 957.69M (+78.9%)
|
1.76B
est: 1.06B (+66.0%)
|
1.81B
est: 1.18B (+53.9%)
|
1.05B
est: 1.09B (-3.7%)
|
552.33M
est: 774.51M (-28.7%)
|
798.40M
est: 712.82M (+12.0%)
|
873.67M
est: 878.08M (-0.5%)
|
893.22M
est: 894.85M (-0.2%)
|
1.04B
est: 1.03B (+1.0%)
|
1.07B
est: 1.14B (-6.4%)
|
1.36B
1.36B – 1.36B
+19.4% YoY
|
1.66B
1.66B – 1.66B
+22.4% YoY
|
1.99B
1.99B – 1.99B
+19.8% YoY
|
| EBIT |
1.45B
est: 556.78M (+160.8%)
|
1.60B
est: 600.98M (+166.3%)
|
1.63B
est: 663.67M (+145.6%)
|
1.65B
est: 739.28M (+122.7%)
|
824.45M
est: 686.83M (+20.0%)
|
306.30M
est: 486.03M (-37.0%)
|
504.30M
est: 447.32M (+12.7%)
|
565.58M
est: 551.02M (+2.6%)
|
565.82M
est: 561.55M (+0.8%)
|
683.93M
est: 653.34M (+4.7%)
|
628.34M
est: 718.53M (-12.6%)
|
858.07M
858.07M – 858.07M
+19.4% YoY
|
1.05B
1.05B – 1.05B
+22.4% YoY
|
1.26B
1.26B – 1.26B
+19.8% YoY
|
| Net Income |
1.27B
est: 1.37B (-7.4%)
|
1.40B
est: 1.50B (-7.2%)
|
1.45B
est: 1.60B (-9.0%)
|
1.46B
est: 1.66B (-11.9%)
|
715.20M
est: 761.25M (-6.0%)
|
60.86M
est: 659.77M (-90.8%)
|
533.73M
est: 545.87M (-2.2%)
|
637.09M
est: 670.47M (-5.0%)
|
580.07M
est: 620.14M (-6.5%)
|
601.57M
est: 629.87M (-4.5%)
|
651.50M
est: 663.32M (-1.8%)
|
841.69M
794.26M – 889.11M
+26.9% YoY
|
1.05B
1.05B – 1.05B
+24.5% YoY
|
1.38B
1.38B – 1.38B
+31.9% YoY
|
| SGA |
1.05B
est: 1.49B (-29.3%)
|
1.21B
est: 1.60B (-24.4%)
|
1.34B
est: 1.77B (-24.6%)
|
1.58B
est: 1.97B (-20.2%)
|
1.85B
est: 1.83B (+1.2%)
|
1.19B
est: 1.30B (-8.5%)
|
1.34B
est: 1.19B (+12.2%)
|
1.33B
est: 1.47B (-9.4%)
|
1.30B
est: 1.50B (-13.1%)
|
1.74B
est: 1.70B (+2.9%)
|
2.00B
est: 1.86B (+7.3%)
|
2.23B
2.23B – 2.23B
+19.4% YoY
|
2.73B
2.73B – 2.73B
+22.4% YoY
|
3.26B
3.26B – 3.26B
+19.8% YoY
|
| EPS |
1.21
est: 1.23 (-1.4%)
|
1.33
est: 1.35 (-1.5%)
|
1.39
est: 1.43 (-2.9%)
|
1.39
est: 1.49 (-6.5%)
|
0.69
est: 0.68 (+1.0%)
|
0.06
est: 0.59 (-90.0%)
|
0.50
est: 0.49 (+2.0%)
|
0.58
est: 0.60 (-3.6%)
|
0.52
est: 0.56 (-6.6%)
|
0.54
est: 0.57 (-4.4%)
|
0.58
est: 0.60 (-2.5%)
|
0.76
0.71 – 0.80
+26.9% YoY
|
0.94
0.94 – 0.94
+24.5% YoY
|
1.24
1.24 – 1.24
+31.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | B+ | 3/5 | 4/5 | 4/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | B | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | B | 3/5 | 4/5 | 3/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 4/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 3/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | KraneShares MSCI All China Health Care Index ETF KURE | 1.05% | 834.5K | 0.79% |
| 2 | HSBC MSCI China A UCITS ETF HMCT.L | 0.13% | 179.7K | 0.30% |
| 3 | iShares MSCI China A ETF CNYA | 0.09% | 207.8K | 0.60% |
| 4 | Amundi MSCI China A UCITS ETF Acc CNAA.L | 0.08% | 117.6K | 0.35% |
| 5 | iShares MSCI China A UCITS ETF CNYE.MI | 0.08% | 80.9K | 0.45% |
| 6 | iShares MSCI China A UCITS ETF CNYA.L | 0.08% | 2.45M | 0.40% |
| 7 | Xtrackers MSCI China A UCITS ETF 1C XX2D.L | 0.07% | 96.8K | 0.35% |
| 8 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.06% | 9.8K | 0.65% |
| 9 | HSBC MSCI AC Asia Pacific ex Japan Climate Paris Aligned UCITS ETF USD HPAJ.L | 0.06% | 10.1K | 0.25% |
| 10 | HSBC MSCI Emerging Markets Climate Paris Aligned UCITS ETF HPEM.L | 0.05% | 21.2K | 0.18% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jianfeng Yang | Secretary of the Board of Directors & Non Independent Director | — | male |
| Jie Yan | GM & Director | — | male |
| Ping Chen | Deputy General Manager | — | male |
| Song Ping Zhao | Deputy General Manager | — | female |
| Xie Heng | Chief Medical Officer | — | — |
| Yun Kong | Chief Financial Officer, Accounting Supervisor & Financial Manager | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002294.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
